21 completed, 8 active not recruiting, 4 recruiting, 4 terminated. 37 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 37 | Completed 21, Active not recruiting 8, Recruiting 4, Terminated 4 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis Ublituximab, Placebo, Fingolimod - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Recruiting | TG Therapeutics, Inc. | 240 | 2026-07-01 | 2026-10-29 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) Ublituximab - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | TG Therapeutics, Inc. | 360 | 2025-07-09 | 2026-10-23 |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. Remibrutinib oral treatment, Ocrelizumab - Relapsing Multiple Sclerosis | Phase 3 | Recruiting | Novartis Pharmaceuticals | 400 | 2025-06-23 | 2026-10-26 |
| Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis CYB704, Ocrevus-EU, Ocrevus-US - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | Sandoz | 183 | 2025-06-10 | 2026-05-29 |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. Tolebrutinib, Placebo, Teriflunomide - Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 3 | Active not recruiting | Sanofi | 2500 | 2024-04-16 | 2026-08-17 |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab Ublituximab, Placebo - Relapsing Multiple Sclerosis | Phase 3 | Recruiting | TG Therapeutics, Inc. | 800 | 2023-06-13 | 2026-10-23 |
| A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV - Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 236 | 2022-05-03 | 2026-08-11 |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) Remibrutinib, Teriflunomide - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 1000 | 2021-12-16 | 2026-08-18 |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) Remibrutinib, Teriflunomide - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 1007 | 2021-12-13 | 2026-08-18 |
| Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Fenebrutinib, Teriflunomide, Placebo - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 751 | 2021-03-24 | 2026-09-17 |
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) Fenebrutinib, Teriflunomide, Placebo - Relapsing Multiple Sclerosis | Phase 3 | Active not recruiting | Hoffmann-La Roche | 746 | 2021-03-17 | 2026-09-21 |
| A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis CNM-Au8 - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Clene Nanomedicine | 55 | 2020-10-22 | 2023-12-08 |
| A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis Ofatumumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 111 | 2020-10-19 | 2026-01-13 |
| 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis Ofatumumab, [F-18]PBR06 - Relapsing Multiple Sclerosis | Phase 3 | Completed | Brigham and Women's Hospital | 10 | 2020-09-21 | 2026-01-27 |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) - Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Phase 3 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 156 | 2020-08-17 | 2026-10-20 |
| An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab Ofatumumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 562 | 2020-07-14 | 2026-04-09 |
| Study of Evobrutinib in Participants With RMS (evolutionRMS 2) Teriflunomide, Evobrutinib - Relapsing Multiple Sclerosis | Phase 3 | Terminated | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1166 | 2020-07-02 | 2025-03-21 |
| Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib - Relapsing Multiple Sclerosis | Phase 3 | Completed | Sanofi | 974 | 2020-06-30 | 2025-07-02 |
| Study of Evobrutinib in Participants With RMS (evolutionRMS 1) Teriflunomide, Evobrutinib - Relapsing Multiple Sclerosis | Phase 3 | Terminated | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1124 | 2020-06-12 | 2025-06-12 |
| Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib - Relapsing Multiple Sclerosis | Phase 3 | Completed | Sanofi | 899 | 2020-06-11 | 2025-07-02 |
Showing 20 of 37. Sign in to see all of them.
Multiple Sclerosis (6) · Recurrence (5) · Multiple Sclerosis, Chronic Progressive (3) · Charcot-Marie-Tooth disease, Type 1F (2) · Demyelinating Diseases (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Optic Nerve Diseases (1) · Optic Neuritis (1)
Autoimmune Diseases (9) · Autoimmune Diseases of the Nervous System (9) · Demyelinating Autoimmune Diseases, CNS (9) · Immune System Diseases (9) · Nervous System Diseases (9) · Demyelinating Diseases (8) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Chronic Disease (3) · Multiple Sclerosis (3) · Cranial Nerve Diseases (1) · Eye Diseases (1)
teriflunomide (10) · ocrelizumab (5) · ofatumumab (5) · ublituximab (4) · Fingolimod Hydrochloride (3) · Interferon beta-1a (3) · peginterferon beta-1a (3) · remibrutinib (3) · Cladribine (2) · Rituximab (2) · Tetanus Toxoid (2) · evobrutinib (2) · fenebrutinib (2) · laquinimod (2) · ozanimod (2)
Novartis Pharmaceuticals (8) · Hoffmann-La Roche (5) · Biogen (3) · Sanofi (3) · TG Therapeutics, Inc. (3) · Celgene (2) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (2) · Novartis (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Brigham and Women's Hospital (1) · Clene Nanomedicine (1) · EMD Serono (1) · Merck KGaA, Darmstadt, Germany (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oslo University Hospital (1)
United States (31) · Poland (25) · Spain (23) · Bulgaria (20) · Germany (19) · Italy (19) · Canada (18) · Czechia (18) · Russia (18) · United Kingdom (18) · Belgium (16) · France (16) · Mexico (15) · Slovakia (15) · Ukraine (15)
Fernando Dangond, MD (1) · George E. Georges, MD (1) · Giancarlo Comi, Prof., MD (1) · Gro Owren Nygaard, MD, PhD (1) · Hanne Flistad Harbo, MD, PhD (1) · Jeffrey A. Cohen, MD (1) · Paolo A. Muraro, MD, PhD (1) · Prof. Timothy Vollmer, MD (1) · Sabine Latour, MD (1) · Tarun Singhal, MD (1)
PMID 37652990, PMID 42546561, PMID 28002679, PMID 32511687, PMID 32690791, PMID 33724637, PMID 34904871, PMID 35672926, PMID 36163349, PMID 36792367, PMID 37148240, PMID 39290861, PMID 39307151, PMID 39965438, PMID 40202623, PMID 40258203, PMID 40554392, PMID 40629721, PMID 42832215, PMID 24221641, PMID 24794721, PMID 25073663, PMID 25265472, PMID 25432952, PMID 25551571, PMID 26195056, PMID 26879276, PMID 28183276, PMID 28450894, PMID 28607743, PMID 29104758, PMID 30043658, PMID 30181780, PMID 31492652, PMID 32757523, PMID 33307998, PMID 35266417, PMID 37094998, PMID 37606897, PMID 37691530, PMID 39018512, PMID 39460719, PMID 40245351, PMID 40248858, PMID 40462564, PMID 40652442, PMID 41196386, PMID 42371147
2019 (4), 2023 (4), 2009 (2), 2025 (2), 2008 (1), 2015 (1), UM1AI109565 (1)